Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte (CT-SP) in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

NCT07028008 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07028008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07028008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte (CT-SP) in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 15, 2025
Completion date
May 28, 2029
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma